https://t.co/gucE3esgh0

Health Canada approves a new trial for Pegevongitide (AV-001) — a made-in-Canada therapy co-developed by Vasomune & AnGes — to protect hemodialysis patients from brain injury by stabilizing the cerebrovasculature.

🧬Next up as part of our #GlobalBiotechWeek celebration is @vasomune who reached the milestone of receiving U.S. FDA Fast Track Designation for their novel investigational medicine AV-001. 👏🏽 We're proud of Vasomune, an #OBIO member, as they continue to advance to the next phase!

Vasomune Therapeutics, Inc. is proud to be in Florida presenting our work at the 2024 Military Health System Research Symposium! With their support we have come a long way from preclinical to Phase 2a with AV-001 for the prevention and treatment of ARDS. https://t.co/QqGIEm9uEJ

Thank you @ARDSALliance and @PaulaBlonski for striving against ARDS, and for reminding us why continued research into prevention and treatment is so important. https://t.co/Z0CTdRYxz3

MHSRS-24-11804 (Full title in article) at 2024 Military Health System Research Symposium. Read more in the link below. https://t.co/dZKPKwGQxq

👏🏽Congratulations to @vasomune on this milestone! We are proud of #OBIO member, Vasomune, as they receive U.S. FDA Fast Track Designation for AV-001. Looking forward to seeing you advance to the next phase!

Ft. @brogoz (CEO of @oncoustics), Alison Smith (co-founder and chief scientist at Roga), @FelixBL92 (CEO of @altislabs), Adam Forman (co-founder of Synakis) and Brian Jahns (COO of @vasomune).

These five startups are working on solutions that could speed up diagnosis, develop promising new therapeutics and improve patient care. Check them out at #MaRSImpactHealth happening June 12 and 13. https://t.co/DqzmMM4NVS

This week @AstraZeneca completed the acquisition of Genesys portfolio company @FusionPharmaInc for US$2.4B! What a journey it has and we're thrilled to see Ontario becoming a global hub of excellence for radiopharmaceuticals. https://t.co/WSRu7onER5

On Monday, June 5th at 3pm PST, Dr Brian Jahns presents the Vasomune Therapeutics story. Join Brian in Theatre 3 for the story of how Vasomune achieved the Fast Track Designation for pneumonia ARDS, and what his vision for the future is. https://t.co/RzrbC80oVF

Congratulations to biopharmaceutical company @vasomune for receiving Fast Track designation by the @US_FDA for investigational medicine AV-001, which aims to address (and prevent) acute respiratory distress syndrome (ARDS).

Vasomune Therapeutics Receives US FDA Fast Track Designation for Novel Investigational Medicine AV-001

アンジェス---Vasomuneとの共同開発品「AV-001」が米国呼吸器学会でポスター発表 - 最新株式ニュース

On May 21, 2024, Vasomune's Dr. Harold Kim will present Phase 1 safety, and pharmacokinetic and pharmacodynamic data for AV-001 as a late-breaking scientific poster at the American Thoracic Society Clinical and Scientific sessions. https://t.co/0bNJO2LsTJ

The agenda may be found at:

Vasomune Therapeutics' Dr Harold Kim, has been selected by the American Thoracic Society to showcase our lead drug candidate AV-001 at the 2024 Respiratory Innovation Summit. Dr. Harold Kim, will speak on May 18th, at 11:30 AM PT, at the Manchester Grand Hyatt, San Diego, CA.

We are pleased to announce that the Independent Data and Safety Monitoring Board recommended the continuation of the Phase 2a trial (NCT05123755) evaluating the efficacy, safety, and tolerability of AV-001 in patients suffering with Acute Respiratory...

Vasomune Therapeutics doses first patient in Phase 2a clinical study to evaluate AV-001 in patients hospitalized with severe COVID-19 disease. https://t.co/AlEI2dpPB8

Our strategic approach to SARS-CoV-2 involves the development of AV-001 for treating patients with severe COVID-19 disease and vaccines to prevent infection